Heat Biologics Inc (NASDAQ:HTBX) was down 11.9% during mid-day trading on Thursday . The stock traded as low as $0.72 and last traded at $0.74. Approximately 1,107,625 shares changed hands during trading, an increase of 118% from the average daily volume of 507,289 shares. The stock had previously closed at $0.84.

Several equities research analysts have recently issued reports on HTBX shares. ValuEngine lowered shares of Heat Biologics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Alliance Global Partners set a $6.00 target price on shares of Heat Biologics and gave the stock a “buy” rating in a research note on Friday, May 17th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $7.67.

The company has a quick ratio of 5.70, a current ratio of 5.70 and a debt-to-equity ratio of 0.01.

Hedge funds have recently bought and sold shares of the company. Virtu Financial LLC boosted its stake in shares of Heat Biologics by 68.9% during the 1st quarter. Virtu Financial LLC now owns 95,215 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 38,843 shares in the last quarter. CVI Holdings LLC purchased a new stake in shares of Heat Biologics during the 4th quarter worth about $1,527,000. Vanguard Group Inc boosted its stake in shares of Heat Biologics by 20.6% during the 3rd quarter. Vanguard Group Inc now owns 798,561 shares of the biopharmaceutical company’s stock worth $1,597,000 after acquiring an additional 136,256 shares in the last quarter. Vanguard Group Inc. lifted its stake in Heat Biologics by 20.6% in the 3rd quarter. Vanguard Group Inc. now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after buying an additional 136,256 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in Heat Biologics in the 1st quarter valued at about $62,000. 12.03% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Heat Biologics (HTBX) Stock Price Down 11.9%” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/heat-biologics-htbx-stock-price-down-11-9/3022171.html.

Heat Biologics Company Profile (NASDAQ:HTBX)

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Recommended Story: What is a trade deficit?

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.